1131992-34-1Relevant articles and documents
KRAS G12C Mutant protein inhibitors
-
Paragraph 0208-0213; 0217, (2021/11/26)
The invention discloses compounds which irreversibly inhibit KRAS G12C mutation. A pharmaceutically acceptable salt and of the compound contains the compound or a salt thereof, and the invention also discloses an application of the compound or a salt and of the compound in the treatment KRAS G12C of a proliferative disease such as a sudden tumor.